Synthetic hydrogels for biomanufacturing of iPSC-derived neural cells for precision medicine
Award amount
$1,546,685Program and phase
SBIR · Phase IIAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- STEM PHARM, INCORPORATED
- Proposal award date
- 2020-08-15
- Contract end date
- 2022-07-31
- UEI
- YTLQLAJ53CB7
- Solicitation number
- PA19-272
- Topic code
- 106
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development and Validation of a CNS Organoid Model of Temporal Lobe Epilepsy for Drug Discovery
- Human Neural Organoid Modeling of Alzheimer's Disease Neuroinflammation for Drug Discovery
- Neural organoid models of the immunological microenvironment of glioblastoma for drug discovery applications
- Hydrogel-enabled self-assembled human brain organoids for neurotoxicity applications
- Hydrogel-enabled self-assembled human brain organoids for developmental neurotoxicity applications
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Clinical Validation of Myoelectric Implant for Intuitive Prosthesis Control
- Targeted ColQ gene therapy for Congenital Myasthenic Syndromes
- Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy
- Developing closed-loop tonic motor activation therapy for treatment of refractory restless legs syndrome
- Engineered microglia for the treatment of Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
Research funding history
9 SBIR/STTR records share this UEI (2017–2024). Reported award amounts total $5,742,982. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services